Ruxolitinib, a potent JAK1/JAK2 inhibitor, induces temporary reductions in the allelic burden of concurrent CSF3R mutations in chronic neutrophilic leukemia

Haematologica. 2017 Jun;102(6):e238-e240. doi: 10.3324/haematol.2017.163790. Epub 2017 Mar 16.

Authors

Arief S Gunawan¹, Donal P McLornan¹, Bridget Wilkins¹, Katherine Waghorn², Yvette Hoade², Nicholas C P Cross², Claire N Harrison³

Affiliations

¹ Guy's and St Thomas' NHS Foundation Trust, London.
² Wessex Regional Genetics Laboratory, Salisbury NHS Foundation Trust and Faculty of Medicine, University of Southampton, UK.
³ Guy's and St Thomas' NHS Foundation Trust, London claire.harrison@gstt.nhs.uk.

No abstract available

Publication types

Case Reports
Letter

MeSH terms

Alleles*
Biopsy
Blood Cell Count
Bone Marrow / pathology
DNA Mutational Analysis
Female
Gene Dosage
Humans
Janus Kinase 1 / antagonists & inhibitors
Janus Kinase 2 / antagonists & inhibitors
Leukemia, Neutrophilic, Chronic / drug therapy*
Leukemia, Neutrophilic, Chronic / genetics*
Leukemia, Neutrophilic, Chronic / pathology
Middle Aged
Mutation*
Nitriles
Protein Kinase Inhibitors / pharmacology
Protein Kinase Inhibitors / therapeutic use*
Pyrazoles / pharmacology
Pyrazoles / therapeutic use*
Pyrimidines
Receptors, Colony-Stimulating Factor / genetics*
Treatment Outcome

Substances

CSF3R protein, human
Nitriles
Protein Kinase Inhibitors
Pyrazoles
Pyrimidines
Receptors, Colony-Stimulating Factor
ruxolitinib
Janus Kinase 1
Janus Kinase 2